AstraZeneca Pharmaceuticals promoter- AB Sweden has decided to provide a voluntary non repayable financial grant of approximately $22.5mio (Rs 1192 mio) to 26,5mio (Rs 1404 mio) over the three years period FY14 - FY16 under a subvention agreement of which the first tranche of $14mio (Rs 740 Mio) shall be provided to the company in the current financial year. Management has factored this voluntary non repayable financial grant by the promoter in its business plan.
Management is reasonably confident, barring unforeseen circumstance, that the strategy plan -- commencing operations at the new tablet facility, retrieving market share of the company products, supplies of which were interrupted last year, further strengthening brand presence, enhancing sales force effectiveness and improved cost management -- will enable the company to achieve in the medium term revenue growth ahead of market and return to profitability.
AstraZeneca operates through two entities, AstraZeneca Pharma India and AstraZeneca India in the country.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1670.40 |
| Dr. Reddys Lab | 1235.00 |
| Cipla | 1232.60 |
| Zydus Lifesciences | 936.50 |
| Lupin | 2327.10 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: